IMNM

Over the past six months, Immunome's stock has been impacted by several events. Positive clinical and regulatory updates included the FDA's acceptance of the NDA for varegacestat, which led to a 29.0% share price increase, and the initiation of the Phase 3 varegacestat trial, along with the dosing of the first patients in the IM-1021 Phase 1 and IM-3050 Phase 1 studies, with the IM-3050 news contributing to an 18.2% share price increase. Financial reporting showed wider net losses in Q2 2026 due to increased R&D and commercialization-readiness spending, with Q2 collaboration revenue falling to zero after the AbbVie agreement ended in 2025, and Q1 2026 also reported an increased net loss. Analyst coverage saw Goldman Sachs, Craig-Hallum, Alliance Global Partners, Wedbush, and Truist Financial initiating or maintaining 'Buy' or 'Outperform' ratings with positive price targets, though Wall Street Zen downgraded the company to a 'strong sell'. Insider activity included the CSO's notification of intent to sell shares and other executive sales. The company also reported inducement grants. Overall, the stock has shown significant growth, with a 1-year change of +163.6% and a 28.36% increase over the past six months.